



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/530,176	03/09/2006	Graham Edmund Kelly		8060
23373	7590	08/04/2008	EXAMINER	
SUGHRUE MION, PLLC 2100 PENNSYLVANIA AVENUE, N.W. SUITE 800 WASHINGTON, DC 20037			PACKARD, BENJAMIN J	
ART UNIT	PAPER NUMBER			
		1612		
MAIL DATE	DELIVERY MODE			
08/04/2008	PAPER			

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/530,176	<b>Applicant(s)</b> KELLY, GRAHAM EDMUND
	<b>Examiner</b> Benjamin Packard	<b>Art Unit</b> 1612

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### **Status**

1) Responsive to communication(s) filed on 29 May 2008.

2a) This action is FINAL.      2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### **Disposition of Claims**

4) Claim(s) 1-4,6-13,15-17,19-21 and 23-25 is/are pending in the application.

4a) Of the above claim(s) 15-17 and 19-21 is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 1-4,6-13, and 23-25 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### **Application Papers**

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### **Priority under 35 U.S.C. § 119**

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### **Attachment(s)**

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date 1pg(4/3/07)

4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_

5) Notice of Informal Patent Application

6) Other: \_\_\_\_\_

## DETAILED ACTION

### *Response to Election/Restrictions*

Applicant's election without traverse of Group I (claims 1-4, 6-13, and 23-25) and the election of the following species: A. compound 12 (dehydroequol); B. ovarian cancer; and C. cisplatin, in the reply filed on 5/29/2008 is acknowledged.

**Claims 15-17 and 19-21** are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventions, there being no allowable generic or linking claim.

### *Claim Rejections - 35 USC § 112*

#### *Claim Rejections - 35 USC § 112 - Scope of Enablement*

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

**Claims 1-4 and 6-13** are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treating ovarian cancer with dehydروequol and cisplatin, does not reasonably provide enablement for increasing the sensitivity of cancer cells or tumors to a chemotherapeutic agent in general. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

To be enabling, the specification of the patent must teach those skilled in the art how to make and use the full scope of the claimed invention without undue

experimentation. In re Wright, 999 F.2d 1557, 1561 (Fed. Cir. 1993). Explaining what is meant by “undue experimentation,” the Federal Circuit has stated:

The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed to enable the determination of how to practice a desired embodiment of the claimed invention. PPG v. Guardian, 75 F.3d 1558, 1564 (Fed. Cir. 1996).<sup>1</sup>

The factors that may be considered in determining whether a disclosure would require undue experimentation are set forth by In re Wands, 8 USPQ2d 1400 (CAFC 1988) at 1404 where the court set forth the eight factors to consider when assessing if a disclosure would have required undue experimentation. Citing Ex parte Forman, 230 USPQ 546 (BdApls 1986) at 547 the court recited eight factors:

- 1) the quantity of experimentation necessary,
- 2) the amount of direction or guidance provided,
- 3) the presence or absence of working examples,
- 4) the nature of the invention,
- 5) the state of the prior art,
- 6) the relative skill of those in the art,
- 7) the predictability of the art, and
- 8) the breadth of the claims.

These factors are always applied against the background understanding that scope of enablement varies inversely with the degree of unpredictability involved. In re Fisher, 57 CCPA 1099, 1108, 427 F.2d 833, 839, 166 USPQ 18, 24 (1970). Keeping that in mind, the Wands factors are relevant to the instant fact situation for the following reasons:

---

<sup>1</sup> As pointed out by the court in In re Angstadt, 537 F.2d 498 at 504 (CCPA 1976), the key word is “undue”, not “experimentation”.

1. The nature of the invention, state and predictability of the art, and relative skill level

The invention relates to increasing the sensitivity of cancer cells or a tumor to a chemotherapeutic agent using isoflavonoids of formula (I). The relative skill of those in the art is high, that of an MD or PhD. That factor is outweighed, however, by the unpredictable nature of the art. As illustrative of the state of the art, the examiner cites As illustrative of the state of the art, the examiner cites Suggitt and Bibby, *Clinical Cancer Research*, 2005, Vol 11, 971-981. Suggitt and Bibby teaches the unpredictability of treating cancer. Note however, that the current human tumor cell line in vitro screen is generally unpredictable. Modern methods are susceptible to false-positive and false-negative results. (page 973 1<sup>st</sup> paragraph on right-hand column). Difficulty in determining results leads to difficulty in testing for effectiveness of compounds, which leads to unpredictability in treating cancers. Here, only ovarian cancer is tested in vivo.

2. The breadth of the claims

The claims are broad in so far as they are related to increasing the sensitivity of cancer cells or a tumor, generally, to chemotherapeutic agents, generally, using a broad range of isoflavonoid compounds.

3. The amount of direction or guidance provided and the presence or absence of working examples

The specification provides no direction or guidance for practicing the claimed invention in its “full scope”. No reasonably specific guidance is provided concerning useful therapeutic protocols for increasing the sensitivity of cancer cells or a tumor to a chemotherapeutic agent using isoflavonoids of formula (I), other than the treatment of ovarian cancer using compound 12 and cisplatin. The latter is corroborated by the working examples. Note, there is no evidence showing the restoration of chemotherapeutic agent sensitivity, as claimed in instant claim 2.

4. The quantity of experimentation necessary

Because of the known unpredictability of the art, and in the absence of experimental evidence, no one skilled in the art would accept the assertion that the instantly claimed agents could be predictably used for increasing the sensitivity of cancer cells or a tumor to a chemotherapeutic agent using isoflavonoids of formula (I) as inferred by the claim and contemplated by the specification. Accordingly, the instant claims do not comply with the enablement requirement of §112, since to practice the claimed invention in its “full scope” a person of ordinary skill in the art would have to engage in undue experimentation, with no assurance of success.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148

USPQ 459 (1966), that are applied for establishing a background for determining

obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

**Claims 1-4, 6-13, and 23-25** are rejected under 35 U.S.C. 103(a) as being unpatentable over Kelly et al (WO98/008503) in view of Ekwuribe et al (US 6,380,405).

Kelly et al teaches treating ovarian cancer (see page 6 line 14) with compound 10, where R11 and R12 can be H (page 5), with the optional double bond (page 5), specifically names as dehydroequol (page 6 line 3)) (also see claims 1, 2, 4).

Kelly et al does not disclose the addition of cisplatin.

Ekwuribe et al teaches the use of cisplatin for the treatment of ovarian cancer (claim 76).

Ekwuribe et al does not teach the addition of dehydroequol

One of ordinary skill in the art would have been motivated to have combined the agents of the primary and secondary references in order to provide a third chemotherapeutic composition useful for the same purpose (treating ovarian cancer). This position is consistent with well-established precedent holding that it is *prima facie* obvious to combine compositions known to be individually useful together so as to

Art Unit: 1612

provide a third composition for the same use. See, e.g., *In re Kerkhoven*, 205 USPQ 1069, 1072 (CCPA 1980). As a result, the instantly claimed method of increasing sensitivity appears to be obvious given the same compounds are administered to the same patient population to treat the same disease.

### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

**Claims 1-4, 6-13, and 23-25 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1-21 of U.S. Patent No. 6,649,648 in view of Ekwuribe et al (US 6,380,405). Although the conflicting claims are not identical, they are not patentably distinct from each other because they teach the administration of the instantly claimed compound for the treatment of ovarian**

cancer. As discussed above, Ekwuribe et al teaches the use of cisplatin for the treatment of ovarian cancer. One of ordinary skill in the art would combine the two means of treating ovarian cancer, making the instant method obvious where the same compounds are used to treat the same patient population.

**Claims 1-4, 6-13, and 23-25** are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-12 of copending Application No. 10/547,077 and claims 7-8 of copending Application No. 10/493390 in view of Ekwuribe et al (US 6,380,405). Although the conflicting claims are not identical, they are not patentably distinct from each other because they teach the administration of the instantly claimed compound for the treatment of ovarian cancer. As discussed above, Ekwuribe et al teaches the use of cisplatin for the treatment of ovarian cancer. One of ordinary skill in the art would combine the two means of treating ovarian cancer, making the instant method obvious where the same compounds are used to treat the same patient population.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

### ***Conclusion***

No claims allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Benjamin Packard whose telephone number is 571-270-3440. The examiner can normally be reached on M-F 8-3:45 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Frederick Krass can be reached on 571-272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Benjamin Packard/  
Patent Examiner, Art Unit 1612

/Frederick Krass/  
Supervisory Patent Examiner, Art Unit 1612